
Stephan Stilgenbauer
Albert Einstein Allee 23
Ulm, BW 89081, Germany
Ulm, BW 89081, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 396 publications
Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 27, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 14, 2026
Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.
Journal: Leukemia & lymphoma
Published: March 17, 2026
Corrigendum to "U-RT1 - A new model for Richter transformation" [Neoplasia Volume 23, Issue 1, January 2021, Pages 140-148].
Journal: Neoplasia (New York, N.Y.)
Published: February 21, 2026
High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.
Journal: Lancet (London, England)
Published: February 19, 2026
Short and complex-Telomeres and genomes in CLL.
Journal: British journal of haematology
Published: January 23, 2026
Shifting clones: CLL evolution under pirtobrutinib treatment.
Journal: Blood
Published: January 01, 2026
Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.
Journal: Blood
Published: December 23, 2025
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
Journal: Lancet (London, England)
Published: December 23, 2025
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.
Journal: The New England journal of medicine
Published: December 08, 2025
IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.
Journal: HemaSphere
Published: December 05, 2025
Last Updated: 09/26/2026